180 Life Sciences Corporate Media Kit

5 FIBROSIS & ANTI-TNF (CLINICAL STAGE)* SYNTHETIC CBD ANALOGS (SCAs) a7nAChR TECHNOLOGIES Repurposing of anti-TNF for major unmet needs, other patented drugs Novel non-psychoactive synthetic CBD analogs Novel α7nAChR agonists TARGETED DISEASES NEAR TERM • Early stage Dupuytren’s disease (DD) • Frozen Shoulder • Post Operative Delirium/Cognitive Deficit (POCD) FURTHER OUT • Non-Alcoholic Steatohepatitis (NASH) • Arthritis • Pain/Inflammation • Smoking cessation induced Ulcerative Colitis (UC) initially • Other inflammatory indications will be targeted after results in UC COMPETITIVE ADVANTAGE • DD : no treatment for early disease • Frozen Shoulder: local steroid only for short term pain relief, does not modulate long-term disease activity • POCD : No treatment available • Novel, >99.5% pure, • Robust batch to batch consistency (non- botanical) • Developing advanced formulation for increased bioavailability • Orally available • Potentially as effective as biologics (like anti-TNF) • Proven lack of toxicity STAGE • DD : Phase 2b/3 in early DD, results Q4 2021* • Frozen Shoulder : Initiate Phase 2 trials Q3 2021 • POCD : Initiate Phase 2 trials Q4 2021 • NASH : Preclinical studies started Q2 2020 • Preclinical – lead SCAs and formulations being identified • Trials planned in arthritis and pain • Preclinical – optimizing new compounds based on safe a7nAchR agonists INTELLECTUAL PROPERTY • Patents issued for treatment of DD & POCD with anti-TNF • Additional patents issued (anti-IL-33) or pending in localized and systemic fibrosis and delivery systems • Patents have a lifespan that expires between 2031 or later • Patent issued for Cyclohexenyl compounds , compositions and uses thereof • Patents pending & to be filed • Patents’ lifespan expires 2036 or later • Three patents issued, one patent pending • Patents’ lifespan expires 2031 or later *Regulatory approvals obtained from the MHRA and CCMO and the relevant accredited ethics committees to perform clinical trials in the UK and The Netherlands. No meetings have been held with, and no applications or requests for approval have been submitted to the FDA for any products at this time. Overview: 180 Life Sciences Development Programs 180 Life Sciences Corp. www.180lifesciences.com Q4 2020